Eciruciclib
CAS No. 1868086-40-1
Eciruciclib( —— )
Catalog No. M28496 CAS No. 1868086-40-1
Eciruciclib is an inhibitor of CDK with antitumor properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 312 | Get Quote |
|
10MG | 500 | Get Quote |
|
25MG | 807 | Get Quote |
|
50MG | 1107 | Get Quote |
|
100MG | 1485 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEciruciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1868086-40-1
-
Formula Weight488.6
-
Molecular FormulaC27H33FN8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (4.09 mM)
-
SMILESCC(C1=C2C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=CC2=NN1C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
TCS 1102
TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).
-
BSJ-4-116
BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM.?It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.